IMRX Immuneering Corp

  1. Stocks
  2. Healthcare
  3. NASDAQ: IMRX

Price (delayed)

$1.64

Market cap

$48.02M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.88

Enterprise value

-$6.92M

Highlights
The debt has declined by 8% year-on-year
Immuneering's revenue has shrunk by 100% QoQ and by 100% YoY
The gross profit has shrunk by 100% QoQ and by 100% YoY
Sector: Healthcare
Industry: Biotechnology
Peers: OMER OMGA

Key stats

What are the main financial stats of IMRX
Market
Shares outstanding
29.28M
Market cap
$48.02M
Enterprise value
-$6.92M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
0.53
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$53.47M
EBITDA
-$52.71M
Free cash flow
-$49.31M
Per share
EPS
-$1.88
Free cash flow per share
-$1.74
Book value per share
$3.09
Revenue per share
$0
TBVPS
$3.36
Balance sheet
Total assets
$102.58M
Total liabilities
$12.01M
Debt
$4.46M
Equity
$90.58M
Working capital
$81.24M
Liquidity
Debt to equity
0.05
Current ratio
11.35
Quick ratio
10.92
Net debt/EBITDA
1.04
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-47.6%
Return on equity
-52.5%
Return on invested capital
-202.2%
Return on capital employed
-56.4%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

IMRX stock price

How has the Immuneering stock price performed over time
Intraday
5.13%
1 week
11.56%
1 month
-31.67%
1 year
-81.36%
YTD
-77.69%
QTD
-43.25%

Financial performance

How have Immuneering's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$58.41M
Net income
-$53.47M
Gross margin
N/A
Net margin
N/A
Immuneering's revenue has shrunk by 100% QoQ and by 100% YoY
The gross profit has shrunk by 100% QoQ and by 100% YoY
The operating income has declined by 13% year-on-year and by 4.1% since the previous quarter
The net income has declined by 6% year-on-year and by 3.6% since the previous quarter

Growth

What is Immuneering's growth rate over time

Valuation

What is Immuneering stock price valuation
P/E
N/A
P/B
0.53
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
IMRX's P/B is 78% less than its last 4 quarters average of 2.4
Immuneering's equity has decreased by 18% YoY and by 13% from the previous quarter
Immuneering's revenue has shrunk by 100% QoQ and by 100% YoY

Efficiency

How efficient is Immuneering business performance
IMRX's return on invested capital has dropped by 107% year-on-year and by 10% since the previous quarter
The ROE has contracted by 32% YoY and by 8% from the previous quarter
The ROA has declined by 30% year-on-year and by 8% since the previous quarter

Dividends

What is IMRX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for IMRX.

Financial health

How did Immuneering financials performed over time
The quick ratio has decreased by 37% from the previous quarter and by 17% YoY
The current ratio has declined by 37% since the previous quarter and by 16% year-on-year
The debt is 95% smaller than the equity
IMRX's debt to equity is up by 25% since the previous quarter and by 25% year-on-year
Immuneering's equity has decreased by 18% YoY and by 13% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.